
NYSEHealthcareMedical - Devices
最新資料
US$42.73
+US$0.69 · +1.64%
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
前收盤價
US$42.73
+US$0.69 · +1.64%
盤中時間採用ET。市場資料可能有所延遲。
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
日內區間
目前US$42.73
52週區間
目前US$42.73
盤中時間採用ET。市場資料可能有所延遲。
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
日內區間
目前US$42.73
52週區間
目前US$42.73
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 200.74億 USD | 167.47億 USD | 142.4億 USD | 126.82億 USD | 118.88億 USD |
| 銷貨成本 | 62.21億 USD | 64.8億 USD | 54.09億 USD | 49.68億 USD | 44.27億 USD |
| 毛利 | 138.53億 USD | 102.67億 USD | 88.31億 USD | 77.14億 USD | 74.61億 USD |
| 研究與開發 | 20.52億 USD | 16.15億 USD | 14.14億 USD | 13.23億 USD | 12.04億 USD |
| 銷售、一般及管理費用 | 68.87億 USD | 59.84億 USD | 51.9億 USD | 45.2億 USD | 42.86億 USD |
| 營業費用 | 98.82億 USD | 76.32億 USD | 66.5億 USD | 58.9億 USD | 55.39億 USD |
| 利息收入 | — | 1.07億 USD | 2200萬 USD | 1000萬 USD | 400萬 USD |
| 利息支出 | 3.49億 USD | 3.87億 USD | 2.72億 USD | 4.64億 USD | 3.49億 USD |
| 折舊和攤銷 | 13.68億 USD | 12.69億 USD | 11.96億 USD | 11.36億 USD | 10.93億 USD |
| 營業利益 | 39.71億 USD | 26.35億 USD | 21.81億 USD | 18.24億 USD | 19.22億 USD |
| 淨利 | 28.86億 USD | 18.54億 USD | 15.93億 USD | 6.98億 USD | 10.4億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$62.71
上漲空間 46.76%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2003年11月6日 | 2:1 | — | — |
股票分割 | 1998年12月1日 | 2:1 | — | — |
已生效 2003年11月6日
2:1
已生效 1998年12月1日
2:1
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T1175.08億0.09%129.35兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI22.82億0.10%2.3兆 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO19.07億0.11%1.8兆 USD0.03%US$715.59+0.61%
iShares Core S&P 500 ETFIVV8.1億0.09%8964.4億 USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY7.42億0.09%8172億 USD0.09%US$778.57+0.60%
Vanguard Morningstar Growth ETFVUG4.41億0.11%3846億 USD0.03%US$91.97+0.72%
State Street Health Care Select Sector SPDR ETFXLV4.34億1.00%435.37億 USD0.08%US$170.81+1.58%
Vanguard Morningstar Value ETFVTV3.43億0.13%2624億 USD0.03%US$220.59+0.44%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Growth ETFVUG
State Street Health Care Select Sector SPDR ETFXLV
Vanguard Morningstar Value ETFVTVAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。